Clinical Trial Management

Trials

Studies that name Clinical Trial Management as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:40 UTC. Showing 200 of 359. Open this list on ClinicalTrials.gov

• Ph3
  NCT07901725 · Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain Amyloidosis

  Regeneron Pharmaceuticals · not yet recruiting · Newly Diagnosed Amyloidosis, Amyloidosis Stage I-IIIA · study director
• Ph3
  NCT07896265 · Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes

  Regeneron Pharmaceuticals · not yet recruiting · Overweight or Obesity Without Diabetes · study director
• Ph1/Ph2
  NCT07887750 · REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)

  Regeneron Pharmaceuticals · not yet recruiting · Diffuse Large B-Cell Lymphoma (DLBCL) · study director
• Ph3
  NCT07876492 · A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants

  Regeneron Pharmaceuticals · not yet recruiting · Secondary Stroke · study director
• Ph1
  NCT07876505 · Healthy Adult Participants Trial Comparing Different Cenvacibart Presentations

  Regeneron Pharmaceuticals · not yet recruiting · Healthy Volunteers · study director
• Ph1/Ph2
  NCT07863024 · Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors

  Regeneron Pharmaceuticals · not yet recruiting · Advanced Solid Tumors · study director
• Ph1
  NCT07861152 · Thyroid-Stimulating Hormone Receptor (TSHR) Blockade With REGN24493 in Adult Participants With Graves' Disease (GD)

  Regeneron Pharmaceuticals · not yet recruiting · Graves' Disease · study director
• Ph3
  NCT07854782 · Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

  Regeneron Pharmaceuticals · recruiting · Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD · study director
• Ph1/Ph2
  NCT07850921 · REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants

  Regeneron Pharmaceuticals · not yet recruiting · Metastatic Castration-Resistant Prostate Cancer, mCRPC · study director
• Ph1/Ph2
  NCT07832370 · A Trial of ALN-6457 in Adult Participants With Symptomatic Prion Disease (PrD)

  Regeneron Pharmaceuticals · not yet recruiting · Prion Disease · study director
• Ph2
  NCT07830329 · Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity

  Regeneron Pharmaceuticals · recruiting · Hidradenitis Suppurativa · study director
• Ph2
  NCT07808515 · A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC)

  Regeneron Pharmaceuticals · not yet recruiting · Locally Advanced Basal Cell Carcinoma · study director
• Ph1
  NCT07759167 · Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis

  Regeneron Pharmaceuticals · recruiting · End-Stage Kidney Disease (ESKD) · study director
• Ph1
  NCT07753148 · Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation

  Regeneron Pharmaceuticals · recruiting · Clonal Cytopenia of Undetermined Significance (CCUS), Low-Risk Myelodysplastic Syndrome (LR-MDS) · study director
• N/A
  NCT07710846 · A Study to Identify and Characterize Adults and Pediatric Participants With Cat and/or Birch Allergy

  Regeneron Pharmaceuticals · not yet recruiting · Conjunctivitis Allergic · study director
• Ph3
  NCT07697599 · Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC)

  Regeneron Pharmaceuticals · recruiting · Venous Thromboembolism (VTE) · study director
• Ph2
  NCT07685808 · Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

  Regeneron Pharmaceuticals · recruiting · Overweight or Obesity · study director
• Ph3
  NCT07675811 · A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy

  Regeneron Pharmaceuticals · recruiting · Allergic Conjunctivitis · study director
• Ph1/Ph2
  NCT07675824 · REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension

  Regeneron Pharmaceuticals · recruiting · Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT) · study director
• Ph2
  NCT07631637 · Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)

  Regeneron Pharmaceuticals · recruiting · Metabolic Dysfunction-Associated Steatohepatitis, MASH · study director
• Ph3
  NCT07626411 · Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation

  Regeneron Pharmaceuticals · recruiting · Atrial Fibrillation (AF) · study director
• Ph4
  NCT07609940 · Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)

  Regeneron Pharmaceuticals · recruiting · Relapsed/Refractory Multiple Myeloma (RRMM) · study director
• Ph1/Ph2
  NCT07594106 · REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma

  Regeneron Pharmaceuticals · recruiting · Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC) · study director
• Ph1
  NCT07594093 · Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity

  Regeneron Pharmaceuticals · recruiting · Overweight or Obesity · study director
• Ph4
  NCT07587658 · This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization

  Regeneron Pharmaceuticals · recruiting · Chronic Obstructive Pulmonary Disease (COPD) · study director
• Ph1/Ph2
  NCT07567469 · A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma

  Regeneron Pharmaceuticals · not yet recruiting · High-Grade Glioma (HGG), Posterior Fossa-A Ependymoma · study director
• Ph3
  NCT07559513 · A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP)

  Regeneron Pharmaceuticals · not yet recruiting · Fibrodysplasia Ossificans Progressiva, FOP · study director
• Ph1
  NCT07543055 · A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread

  Regeneron Pharmaceuticals · recruiting · Prostate Cancer · study director
• Ph2
  NCT07527910 · A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

  Regeneron Pharmaceuticals · recruiting · Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) · study director
• Ph1
  NCT07527923 · First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis

  Regeneron Pharmaceuticals · recruiting · Healthy Volunteer, Atopic Dermatitis · study director
• Ph1
  NCT07526116 · A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy Adults

  Regeneron Pharmaceuticals · recruiting · Healthy Volunteer · study director
• Ph3
  NCT07493304 · Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers

  Regeneron Pharmaceuticals · recruiting · Venous Thromboembolism (VTE) · study director
• Ph2
  NCT07477704 · A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia

  Regeneron Pharmaceuticals · active not recruiting · Hypercholesterolemia · study director
• Ph1/Ph2
  NCT07455851 · A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma

  Regeneron Pharmaceuticals · recruiting · Relapsed Refractory Multiple Myeloma (RRMM) · study director
• Ph3
  NCT07430956 · Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable

  Regeneron Pharmaceuticals · recruiting · Atrial Fibrillation (AF) · study director
• Ph2
  NCT07431086 · Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US

  Regeneron Pharmaceuticals · active not recruiting · Overweight or Obesity · study director
• Ph2/Ph3
  NCT07428369 · A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)

  Regeneron Pharmaceuticals · withdrawn · Multiple Myeloma (MM) · study director
• Ph3
  NCT07410117 · REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

  Regeneron Pharmaceuticals · recruiting · Cancer-Associated Thrombosis (CAT) · study director
• Ph3
  NCT07393282 · A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

  Regeneron Pharmaceuticals · recruiting · High Risk Smoldering Multiple Myeloma (HR-SMM) · study director
• Ph3
  NCT07318610 · Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease

  Regeneron Pharmaceuticals · recruiting · Peripheral Artery Disease (PAD) · study director
• Ph2
  NCT07318597 · Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)

  Regeneron Pharmaceuticals · recruiting · Pulmonary Arterial Hypertension (PAH) · study director
• Ph3
  NCT07309432 · Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy

  Regeneron Pharmaceuticals · terminated · Allergic Conjunctivitis · study director
• Ph2
  NCT07271186 · Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease

  Regeneron Pharmaceuticals · recruiting · Diabetic Kidney Disease (DKD) · study director
• Ph2
  NCT07235917 · A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea

  Regeneron Pharmaceuticals · recruiting · Functional Hypothalamic Amenorrhea, FHA · study director
• Ph1
  NCT07230834 · Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants

  Regeneron Pharmaceuticals · recruiting · Geographic Atrophy (GA) · study director
• Ph3
  NCT07222761 · A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

  Regeneron Pharmaceuticals · recruiting · Relapsed and/or Refractory Multiple Myeloma (RRMM) · study director
• Ph3
  NCT07220785 · Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy

  Regeneron Pharmaceuticals · recruiting · Generalized Lipodystrophy · study director
• Ph3
  NCT07220772 · A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults

  Regeneron Pharmaceuticals · recruiting · Monogenic Obesity · study director
• Ph1/Ph2
  NCT07218770 · A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants

  Regeneron Pharmaceuticals · terminated · Active Noninfectious Uveitis Affecting the Posterior Segment · study director
• Ph1
  NCT07216066 · First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD)

  Regeneron Pharmaceuticals · recruiting · Parkinsons Disease · study director
• Ph3
  NCT07213778 · REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants

  Regeneron Pharmaceuticals · recruiting · Symptomatic Venous Thromboembolism (VTE) · study director
• Ph1/Ph2
  NCT07187401 · A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor

  Regeneron Pharmaceuticals · recruiting · Paroxysmal Nocturnal Hemoglobinuria (PNH), Persistent Anemia · study director
• Ph4
  NCT07187089 · Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With Dupilumab

  Regeneron Pharmaceuticals · withdrawn · Severe Atopic Dermatitis (AD) · study director
• Ph2
  NCT07175428 · Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

  Regeneron Pharmaceuticals · recruiting · Atrial Fibrillation (AF) · study director
• Ph2
  NCT07154290 · A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

  Regeneron Pharmaceuticals · recruiting · Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer · study director
• Ph3
  NCT07154745 · A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently

  Regeneron Pharmaceuticals · recruiting · Paroxysmal Nocturnal Hemoglobinuria · study director
• Ph4
  NCT07142343 · A Study to Test the Safety of Pozelimab in Pediatric Participants 1 to 5 Years of Age With a Rare Disease Called CHAPLE (Complement Hyperactivation, Angiopathic Thrombosis, Protein-losing Enteropathy) Disease

  Regeneron Pharmaceuticals · recruiting · CHAPLE Disease · study director
• Ph3
  NCT07112378 · A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis

  Regeneron Pharmaceuticals · recruiting · Eosinophilic Esophagitis (EoE) · study director
• N/A
  NCT07105228 · Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study

  Regeneron Pharmaceuticals · completed · Retinal Vasculitis · study director
• Ph3
  NCT07015905 · REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults

  Regeneron Pharmaceuticals · recruiting · Venous Thromboembolism (VTE) · study director
• Ph1
  NCT06975787 · Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis

  Regeneron Pharmaceuticals · recruiting · Lupus Nephritis (LN) · study director
• Ph1
  NCT06970405 · Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopausal Women

  Regeneron Pharmaceuticals · withdrawn · Obesity · study director
• Ph2
  NCT06848088 · A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment

  Regeneron Pharmaceuticals · active not recruiting · Melanoma · study director
• Ph1/Ph2
  NCT06836609 · A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)

  Regeneron Pharmaceuticals · active not recruiting · Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis · study director
• Ph2
  NCT06833190 · REGN5381 in Adult Participants With Uncontrolled Hypertension

  Regeneron Pharmaceuticals · terminated · Uncontrolled Hypertension · study director
• N/A
  NCT06798298 · A Safety and Efficacy Long-Term Follow-up Study of Adult Participants Treated With Gene Modified T Cells

  Regeneron Pharmaceuticals · recruiting · Long Term Safety Following GM T Cell Therapy · study director
• Ph2
  NCT06787612 · Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

  Regeneron Pharmaceuticals · recruiting · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer · study director
• Ph1
  NCT06784349 · ALN-APOC3 in Adult Participants With Dyslipidemia

  Regeneron Pharmaceuticals · completed · Dyslipidemia · study director
• Ph2
  NCT06769698 · A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  Regeneron Pharmaceuticals · recruiting · Head and Neck Squamous Cell Carcinoma (HNSCC) · study director
• N/A
  NCT06693531 · A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care

  Regeneron Pharmaceuticals · active not recruiting · Eosinophilic Esophagitis (EoE) · study director
• Ph1
  NCT06669234 · Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults

  Regeneron Pharmaceuticals · completed · Healthy Volunteer · study director
• Ph1/Ph2
  NCT06669247 · A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma

  Regeneron Pharmaceuticals · recruiting · Relapsed/Refractory Multiple Myeloma · study director
• Ph1
  NCT06665828 · Phase 1 Safety and Tolerability Study of REGN9533 in Healthy Adults

  Regeneron Pharmaceuticals · completed · Healthy Volunteer · study director
• Ph2
  NCT06608901 · A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension

  Regeneron Pharmaceuticals · completed · Sepsis-Induced Hypotension · study director
• Ph2
  NCT06593600 · Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)

  Regeneron Pharmaceuticals · completed · Postural Orthostatic Tachycardia Syndrome (POTS) · study director
• Ph3
  NCT06602739 · A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy

  Regeneron Pharmaceuticals · completed · Allergic Conjunctivitis · study director
• Ph3
  NCT06602726 · A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy

  Regeneron Pharmaceuticals · completed · Allergic Conjunctivitis · study director
• Ph3
  NCT06585410 · Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

  Regeneron Pharmaceuticals · recruiting · Cutaneous Squamous Cell Carcinoma (CSCC) · study director
• Ph4
  NCT06572228 · Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

  Regeneron Pharmaceuticals · active not recruiting · Asthma · study director
• Ph3
  NCT06548100 · A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)

  Regeneron Pharmaceuticals · completed · Generalized Lipodystrophy · study director
• Ph3
  NCT06541704 · A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

  Regeneron Pharmaceuticals · recruiting · Age-related Macular Degeneration (AMD), Geographic Atrophy (GA) · study director
• N/A
  NCT06541795 · Evaluation of AcrySof IQ Vivity Extended Vision Intraocular Lenses

  Alcon Research · withdrawn · Aphakia, Presbyopia, Residual Refractive Cylinder · study director
• Ph3
  NCT06491914 · A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)

  Regeneron Pharmaceuticals · active not recruiting · Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema · study director
• Ph1
  NCT06469281 · A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

  Regeneron Pharmaceuticals · recruiting · Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer · study director
• Ph2
  NCT06465329 · A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

  Regeneron Pharmaceuticals · active not recruiting · Non Small Cell Lung Cancer, NSCLC · study director
• Ph2
  NCT06454630 · A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants

  Regeneron Pharmaceuticals · completed · Venous Thromboembolism · study director
• Ph1
  NCT06452771 · A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults

  Regeneron Pharmaceuticals · active not recruiting · Healthy Volunteers With Hyperlipidemia · study director
• Ph1
  NCT06444178 · Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants

  Regeneron Pharmaceuticals · completed · Healthy Volunteers · study director
• Ph2
  NCT06421636 · A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body

  Regeneron Pharmaceuticals · active not recruiting · Non-Transfusion Dependent Beta-Thalassemia (NTDT) · study director
• Ph1/Ph2
  NCT06413680 · A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

  Regeneron Pharmaceuticals · recruiting · Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors · study director
• N/A
  NCT06398080 · An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting

  Regeneron Pharmaceuticals · withdrawn · Neovascular Age-related Macular Degeneration (nAMD), Wet Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME) · study director
• Ph2
  NCT06384820 · Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)

  Regeneron Pharmaceuticals · withdrawn · Cutaneous Squamous Cell Carcinoma · study director
• Ph1/Ph2
  NCT06379789 · A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

  Regeneron Pharmaceuticals · recruiting · Hemophilia B · study director
• Ph1
  NCT06369467 · Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy

  Regeneron Pharmaceuticals · active not recruiting · Food Allergy · study director
• Ph1/Ph2
  NCT06351592 · First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)

  Regeneron Pharmaceuticals · recruiting · Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene · study director
• Ph2
  NCT06299098 · A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation

  Regeneron Pharmaceuticals · active not recruiting · Obesity · study director
• Ph2
  NCT06299111 · A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)

  Regeneron Pharmaceuticals · completed · Venous Thromboembolism · study director
• Ph1/Ph2
  NCT06292780 · A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

  Regeneron Pharmaceuticals · recruiting · Relapsed/Refractory Systemic Light Chain Amyloidosis · study director
• N/A
  NCT06285695 · Clareon Toric Study (T2-T9)

  Alcon Research · completed · Aphakia, Corneal Astigmatism · study director
• N/A
  NCT06269133 · Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Participants

  Regeneron Pharmaceuticals · active not recruiting · Advanced Non-small Cell Lung Cancer · study director
• Ph3
  NCT06246916 · A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

  Regeneron Pharmaceuticals · recruiting · Melanoma · study director
• Ph3
  NCT06230224 · A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

  Regeneron Pharmaceuticals · active not recruiting · B-Cell Non-Hodgkin Lymphoma (B-NHL) · study director
• Ph2
  NCT06190951 · A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

  Regeneron Pharmaceuticals · active not recruiting · Melanoma · study director
• Ph2
  NCT06161441 · A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

  Regeneron Pharmaceuticals · active not recruiting · Resectable Non-small Cell Lung Cancer · study director
• Ph3
  NCT06149286 · A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

  Regeneron Pharmaceuticals · recruiting · Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) · study director
• Ph2
  NCT06140524 · A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

  Regeneron Pharmaceuticals · recruiting · Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM) · study director
• Ph1
  NCT06137482 · A Study to See How Safe and Tolerable Different Doses of REGN13335 Are When Administered Intravenously (IV) or Subcutaneously (SC) to Healthy Adult Participants

  Regeneron Pharmaceuticals · completed · Healthy Volunteers · study director
• Ph3
  NCT06097364 · A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

  Regeneron Pharmaceuticals · active not recruiting · Follicular Lymphoma (FL) · study director
• Ph3
  NCT06091254 · A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

  Regeneron Pharmaceuticals · recruiting · Follicular Lymphoma (FL) · study director
• Ph3
  NCT06091865 · A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

  Regeneron Pharmaceuticals · recruiting · Diffuse Large B-cell Lymphoma (DLBCL) · study director
• N/A
  NCT06064656 · A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP)

  Regeneron Pharmaceuticals · completed · Fibrodysplasia Ossificans Progressiva (FOP) · study director
• Ph1
  NCT06024408 · A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor

  Regeneron Pharmaceuticals · completed · Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH), Genetic Risk Factor · study director
• N/A
  NCT06019481 · A Natural History Study in Pediatric Participants With Hearing Loss Due to OTOF, GJB2, or GJB2/GJB6 Mutations

  Regeneron Pharmaceuticals · withdrawn · Congenital Hearing Loss Secondary to Biallelic Mutations in the Otoferlin Gene (OTOF), Biallelic Mutations in the Gap Junction Beta 2 (GJB2) Gene, Digenic Mutations in GJB2/Gap Junction Beta 6 (GJB6) Genes · study director
• Ph3
  NCT05989126 · Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)

  Regeneron Pharmaceuticals · completed · Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD) · study director
• Ph1
  NCT05970718 · A Trial to Learn if Different Doses of REGN7544 Are Safe in Healthy Adult Participants

  Regeneron Pharmaceuticals · completed · Healthy Volunteers · study director
• Ph2
  NCT05955508 · A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

  Regeneron Pharmaceuticals · active not recruiting · Smoldering Multiple Myeloma (SMM) · study director
• Ph1
  NCT05923424 · A Trial to Learn if Different Doses of REGN17092 Are Safe in Healthy Adults

  Regeneron Pharmaceuticals · completed · Healthy Volunteers · study director
• Ph2
  NCT05831176 · A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have

  Regeneron Pharmaceuticals · active not recruiting · Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID) · study director
• Ph1/Ph2
  NCT05828511 · A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

  Regeneron Pharmaceuticals · active not recruiting · Multiple Myeloma · study director
• Ph2/Ph3
  NCT05800015 · A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

  Regeneron Pharmaceuticals · active not recruiting · Non-small Cell Lung Cancer · study director
• N/A
  NCT05791695 · A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022

  Regeneron Pharmaceuticals · completed · Intraocular Inflammation, Suspected Endophthalmitis · study director
• Ph1/Ph2
  NCT05788536 · A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations

  Regeneron Pharmaceuticals · recruiting · Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) · study director
• Ph2/Ph3
  NCT05785767 · A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

  Regeneron Pharmaceuticals · active not recruiting · Advanced Non-Small Cell Lung Cancer · study director
• Ph3
  NCT05744921 · A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works

  Regeneron Pharmaceuticals · recruiting · Paroxysmal Nocturnal Hemoglobinuria · study director
• Ph3
  NCT05730036 · A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

  Regeneron Pharmaceuticals · recruiting · Relapsed Refractory Multiple Myeloma (RRMM) · study director
• Ph1
  NCT05685173 · A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

  Regeneron Pharmaceuticals · recruiting · B-cell Non-Hodgkins Lymphoma (B-NHL) · study director
• N/A
  NCT05673967 · Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma

  Regeneron Pharmaceuticals · completed · Relapsed and Refractory Multiple Myeloma (RRMM) · study director
• Ph1/Ph2
  NCT05648214 · A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

  Regeneron Pharmaceuticals · recruiting · Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) · study director
• Ph2
  NCT05618808 · A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants

  Regeneron Pharmaceuticals · completed · Venous Thromboembolism · study director
• Ph3
  NCT05608291 · A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

  Regeneron Pharmaceuticals · active not recruiting · Melanoma · study director
• Ph1
  NCT05603195 · A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants

  Regeneron Pharmaceuticals · completed · Healthy Volunteer · study director
• Ph4
  NCT05590585 · Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial

  Regeneron Pharmaceuticals · completed · Moderate-to-Severe Atopic Dermatitis, Atopic Eczema · study director
• N/A
  NCT05568459 · A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy

  Regeneron Pharmaceuticals · active not recruiting · Hemophilia B · study director
• Ph2
  NCT05557591 · A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

  Regeneron Pharmaceuticals · active not recruiting · Advanced Non-Small Cell Lung Cancer · study director
• N/A
  NCT05546957 · Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants

  Regeneron Pharmaceuticals · completed · Healthy Volunteer · study director
• Ph2
  NCT05519475 · A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

  Regeneron Pharmaceuticals · recruiting · Metabolic Dysfunction-Associated SteatoHepatitis (MASH) · study director
• Ph1
  NCT05505448 · A Trial to Learn if a COVID-19 Therapeutic is Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants

  Regeneron Pharmaceuticals · completed · Healthy · study director
• Ph1
  NCT05481333 · A Trial to Learn if REGN7999 is Safe and Well Tolerated, and How it Works in the Body of Healthy Participants

  Regeneron Pharmaceuticals · completed · Healthy · study director
• Ph2
  NCT05430919 · Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants

  Regeneron Pharmaceuticals · completed · Allergic Rhinitis, Conjunctivitis · study director
• N/A
  NCT05423327 · Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH)

  Regeneron Pharmaceuticals · terminated · Non-alcoholic Steatohepatitis (NASH) · study director
• Ph3
  NCT05394116 · A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)

  Regeneron Pharmaceuticals · active not recruiting · Fibrodysplasia Ossificans Progressiva · study director
• N/A
  NCT05363319 · An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe

  Regeneron Pharmaceuticals · active not recruiting · Non-small Cell Lung Cancer · study director
• Ph3
  NCT05352672 · Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

  Regeneron Pharmaceuticals · active not recruiting · Melanoma · study director
• Ph2
  NCT05353166 · REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure

  Regeneron Pharmaceuticals · completed · Heart Failure · study director
• Ph1/Ph2
  NCT05348889 · First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies

  Chimagen Biosciences, Ltd · terminated · Non-Hodgkin's Lymphoma (disorder), Acute Lymphoid Leukemia, Disease (disorder) · study director
• N/A
  NCT05338892 · Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

  Regeneron Pharmaceuticals · completed · Diffuse Large B-Cell Lymphoma · study director
• N/A
  NCT05338879 · Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed or Refractory Follicular Lymphoma

  Regeneron Pharmaceuticals · completed · Relapsed/Refractory Follicular Lymphoma · study director
• Ph1
  NCT05293678 · Safety and Tolerability of Regeneron Anti-SARS-CoV-2 Monoclonal Antibody/Ies in Adult Healthy Volunteers as Related to COVID-19

  Regeneron Pharmaceuticals · completed · Healthy · study director
• Ph1
  NCT05291546 · A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9035 in Healthy Adult Volunteers and Mildly Hypertensive Participants

  Regeneron Pharmaceuticals · completed · Healthy Volunteers · study director
• N/A
  NCT05203380 · Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis

  Regeneron Pharmaceuticals · completed · Moderate-to-severe Atopic Dermatitis · study director
• Ph1
  NCT05181683 · COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers

  Regeneron Pharmaceuticals · completed · Healthy, Chronic Stable Illness · study director
• Ph1
  NCT05169489 · A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)

  Regeneron Pharmaceuticals · terminated · Diffuse Large B Cell Lymphoma (DLBCL) · study director
• Ph1
  NCT05137054 · A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

  Regeneron Pharmaceuticals · recruiting · Multiple Myeloma · study director
• Ph3
  NCT05133531 · A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment

  Regeneron Pharmaceuticals · completed · Paroxysmal Nocturnal Hemoglobinuria · study director
• Ph3
  NCT05131204 · Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria

  Regeneron Pharmaceuticals · terminated · Paroxysmal Nocturnal Hemoglobinuria · study director
• Ph1/Ph2
  NCT05125016 · A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer

  Regeneron Pharmaceuticals · recruiting · Metastatic Castration-resistant Prostate Cancer · study director
• N/A
  NCT05106387 · An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant

  Regeneron Pharmaceuticals · recruiting · Chronic Kidney Disease (CKD) · study director
• Ph1
  NCT05102136 · Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9933 in Adult Healthy Volunteers

  Regeneron Pharmaceuticals · completed · Healthy Volunteers · study director
• Ph1/Ph2
  NCT05092347 · A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)

  Regeneron Pharmaceuticals · active not recruiting · Chronic Kidney Disease (CKD) · study director
• Ph1
  NCT05092581 · COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19

  Regeneron Pharmaceuticals · terminated · COVID-19 · study director
• Ph2
  NCT05088460 · A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)

  Regeneron Pharmaceuticals · terminated · Familial Partial Lipodystrophy, Metabolic Abnormalities · study director
• Ph1/Ph2
  NCT05081388 · COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease

  Regeneron Pharmaceuticals · terminated · SARS-CoV-2 · study director
• Ph3
  NCT05074433 · A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults

  Regeneron Pharmaceuticals · terminated · Immunocompromised · study director
• Ph3
  NCT05070858 · A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

  Regeneron Pharmaceuticals · active not recruiting · Generalized Myasthenia Gravis · study director
• Ph2
  NCT04992273 · COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age

  Regeneron Pharmaceuticals · terminated · COVID-19 · study director
• Ph3
  NCT04981717 · A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat

  Regeneron Pharmaceuticals · terminated · Allergic Rhinitis Due to Cat Allergy · study director
• Ph1
  NCT04982224 · Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer

  Regeneron Pharmaceuticals · terminated · Advanced NSCLC · study director
• N/A
  NCT04959448 · Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)

  Regeneron Pharmaceuticals · active not recruiting · Chronic Rhinosinusitis With Nasal Polyposis · study director
• Ph1
  NCT04940364 · A Study to Examine the Safety, Tolerability and Biological Effects of Single Doses of Subcutaneously and Intravenously Administered Pozelimab as Monotherapy and in Combination With Single Doses of Subcutaneously Administered Cemdisiran in Adult Japanese Healthy Volunteers

  Regeneron Pharmaceuticals · completed · Healthy · study director
• Ph2
  NCT04916002 · A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

  Regeneron Pharmaceuticals · terminated · Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma · study director
• Ph2
  NCT04888507 · Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy

  Regeneron Pharmaceuticals · completed · Paroxysmal Nocturnal Hemoglobinuria · study director
• Ph2
  NCT04863014 · Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis

  Regeneron Pharmaceuticals · terminated · Hypertriglyceridemia · study director
• Ph2
  NCT04852978 · COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers

  Regeneron Pharmaceuticals · completed · Healthy, Chronic Stable Illness · study director
• Ph2
  NCT04811716 · Pozelimab and Cemdisiran Combination Treatment in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab Monotherapy

  Regeneron Pharmaceuticals · completed · Paroxysmal Nocturnal Hemoglobinuria · study director
• Ph3
  NCT04709575 · Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis

  Regeneron Pharmaceuticals · completed · Allergic Rhinitis, Conjunctivitis · study director
• Ph2
  NCT04698187 · CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma

  Regeneron Pharmaceuticals · terminated · Melanoma, Advanced Melanoma, Metastatic Melanoma · study director
• Ph2/Ph3
  NCT04695977 · CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma

  Regeneron Pharmaceuticals · terminated · Melanoma, Advanced Melanoma, Metastatic Melanoma · study director
• Ph2
  NCT04666441 · COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection

  Regeneron Pharmaceuticals · completed · COVID-19 · study director
• Ph2
  NCT04646005 · Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy

  Regeneron Pharmaceuticals · completed · Cervical Cancer · study director
• Ph2
  NCT04633278 · CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  Regeneron Pharmaceuticals · terminated · Squamous Cell Carcinoma of Head and Neck · study director
• Ph1/Ph2
  NCT04626635 · A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

  Regeneron Pharmaceuticals · active not recruiting · Advanced Solid Tumors · study director
• Ph1
  NCT04616079 · Ascending Dose Study of the Safety and Tolerability of REGN6490 in Healthy Volunteers

  Regeneron Pharmaceuticals · terminated · Healthy Volunteer · study director
• Ph1
  NCT04616105 · Study of the Safety, Tolerability, and Pharmacokinetics of REGN6490 in Healthy Japanese Adult Volunteers

  Regeneron Pharmaceuticals · terminated · Healthy Volunteer · study director
• Ph1
  NCT04601844 · Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pozelimab in Combination With Cemdisiran in Healthy Adult Volunteers

  Regeneron Pharmaceuticals · completed · Healthy · study director
• Ph1/Ph2
  NCT04590326 · A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

  Regeneron Pharmaceuticals · recruiting · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer · study director
• Ph3
  NCT04577820 · Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)

  Regeneron Pharmaceuticals · withdrawn · Fibrodyplasia Ossificans Progressiva (FOP), Heterotopic Ossification (HO) · study director
• Ph1
  NCT04519437 · Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19

  Regeneron Pharmaceuticals · completed · Healthy, Chronic Stable Illness · study director
• N/A
  NCT04515524 · Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)

  Regeneron Pharmaceuticals · active not recruiting · Retinopathy of Prematurity · study director
• Ph1
  NCT04506645 · Study to Assess the Safety, Tolerability, and Pharmacokinetics of REGN5381 (an NPR1 Agonist) in Adult Humans

  Regeneron Pharmaceuticals · completed · Healthy · study director
• Ph1
  NCT04491838 · Study of a Single Subcutaneous Dose of Pozelimab Produced From Two Different Manufacturing Processes in Healthy Adult Participants

  Regeneron Pharmaceuticals · completed · Healthy Volunteer · study director
• Ph1
  NCT04465487 · Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies

  Regeneron Pharmaceuticals · terminated · Squamous Cell Carcinoma of Head and Neck · study director
• Ph3
  NCT04452318 · COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay

  Regeneron Pharmaceuticals · completed · Healthy Participants · study director
• Ph2
  NCT04442269 · Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)

  Regeneron Pharmaceuticals · completed · Allergic Bronchopulmonary Aspergillosis · study director
• Ph2/Ph3
  NCT04429503 · Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease

  Regeneron Pharmaceuticals · completed · Diabetic Macular Edema, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus · study director
• Ph3
  NCT04425629 · Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19

  Regeneron Pharmaceuticals · terminated · COVID-19 · study director
• Ph1/Ph2
  NCT04426695 · Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19

  Regeneron Pharmaceuticals · completed · COVID-19 · study director
• Ph3
  NCT04417894 · A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)

  Regeneron Pharmaceuticals · completed · Moderate to Severe Atopic Hand and Foot Dermatitis · study director
• Ph1
  NCT04409080 · REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy

  Regeneron Pharmaceuticals · terminated · Severe Aplastic Anemia (SAA) · study director
• Ph3
  NCT04394351 · Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)

  Regeneron Pharmaceuticals · completed · Eosinophilic Esophagitis (EoE) · study director
• Ph2
  NCT04373083 · Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma

  Regeneron Pharmaceuticals · withdrawn · Hodgkin Lymphoma · study director

Grants

NIH projects from RePORTER, fetched 2026-11-12 11:40 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.